New eczema drug enters first human tests
NCT ID NCT07488065
First seen Mar 30, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goals are to check safety and how the body processes the drug. A small group of eczema patients will also be monitored for skin improvement. The study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, 200040, China
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.